

Zetia® (ezetimibe) – First-Time Generic

- On December 12, 2016, <u>Endo announced</u> the launch of its <u>AB-rated</u> generic version of Merck's <u>Zetia</u> (<u>ezetimibe</u>) 10 mg tablets, to treat primary hyperlipidemia, homozygous familial hypercholesterolemia (HoFH), and homozygous sitosterolemia.
 - One of Endo's operating companies, Par Pharmaceuticals, has begun shipping generic Zetia. Par was granted 180 days of exclusivity.
- Ezetimibe is also available as combination products, <u>Liptruzet[™] (ezetimibe/atorvastatin)</u> and <u>Vytorin[®] (ezetimibe/simvastatin)</u>.
 - Both Liptruzet and Vytorin are indicated to treat primary hyperlipidemia and HoFH.
- According to IMS Health data, the U.S. sales of Zetia were approximately \$2.614 billion for the 12 months ending on September 30, 2016.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.